









Markets
/
Stocks
/
nasdaq-nrxp
/

NRX Pharmaceuticals Inc

NRXP

2.970USD

-0.010-0.34%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

57.84MMarket Cap

LossP/E TTM



NRX Pharmaceuticals Inc

2.970

-0.010-0.34%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

251 / 506

Overall Ranking

409 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

36.250

Target Price

+1116.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Fairly Valued

The company’s latest PE is -1.34, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.07M shares, increasing 22.10% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 452.18K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.35, which is -23.63% below the recent high of -1.03 and -627.42% above the recent low of -9.78.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 251/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for NRX Pharmaceuticals Inc is 37.00, with a high of 46.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

36.250

Target Price

+1120.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

NRX Pharmaceuticals Inc

NRXP

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.55, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.36 and the support level at 2.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.060

Buy

RSI(14)

56.007

Neutral

STOCH(KDJ)(9,3,3)

55.341

Neutral

ATR(14)

0.239

Low Volatility

CCI(14)

44.281

Neutral

Williams %R

24.126

Buy

TRIX(12,20)

0.488

Sell

StochRSI(14)

48.551

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.970

Sell

MA10

2.949

Buy

MA20

2.772

Buy

MA50

2.777

Buy

MA100

2.809

Buy

MA200

2.580

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 29.31%, representing a quarter-over-quarter increase of 12.39%. The largest institutional shareholder is The Vanguard, holding a total of 452.18K shares, representing 1.90% of shares outstanding, with 15.50% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Anson Funds Management LP.

1.18M

+535.06%

Javitt (Jonathan C)

1.52M

-0.01%

Glytech LLC

963.48K

The Vanguard Group, Inc.

Star Investors

388.93K

+61.84%

AdvisorShares Investments, LLC

286.80K

-7.58%

Hurvitz (Chaim)

221.48K

+0.00%

Geode Capital Management, L.L.C.

134.66K

+81.35%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.